stockrow
Friday 6 November 2026
Export RVMD’s income statement to Excel — free account
Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
192.35
14.70
+8.27%
Follow RVMD
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
210.96 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(106.15) | — | — | — | |
P/B ratio |
18.37 | — | — | — | |
Price to Tangible BV |
18.92 | — | — | — | |
EV/Sales |
198.45 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(29.00) | — | — | — | |
EV/FCF |
(28.81) | — | — | — | |
Quick Ratio |
7.68 | 11.12 | 6.59 | 6.97 | |
Current Ratio |
8.36 | 11.38 | 6.80 | 7.14 | |
Net Debt/EBITDA |
0.00 | 5.75 | 3.67 | 4.86 | |
Debt/Assets |
0.00% | 23.96% | 12.45% | 11.40% | |
Debt/Equity |
0.00 | 0.40 | 0.19 | 0.16 | |
Asset Turnover |
0.06 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.02 | 0.60 | 0.78 | 0.75 | |
Capex/Depreciation |
0.00 | (13.69) | (1.17) | (13.01) | |
Interest Coverage |
(11.04) | (21.24) | (36.50) | (30.30) | |
Research and Development Expense of Revenue |
211.12% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
31.70% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.05 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(4.44%) | — | — | — | |
Free Cash Flow Yield |
(3.27%) | — | — | — | |
Revenue per Share |
0.92 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.93) | (1.84) | (1.79) | (1.44) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(1.95) | (1.85) | (1.80) | (1.45) | |
Cash per Share |
16.99 | 18.67 | 9.63 | 10.65 | |
Shareholders Equity per Share |
11.17 | 12.36 | 7.57 | 8.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.17 | 12.36 | 7.57 | 8.58 | |
Free Cash Flow |
(419.35) | (389.60) | (355.70) | (276.16) | |
Working Capital |
3,501.03 | 3,674.28 | 1,678.31 | 1,784.61 | |
Capital Expenditures |
(3.70) | (2.29) | (1.54) | (1.92) | |
Net Current Asset Value |
2,074.69 | 2,311.31 | 1,214.09 | 1,351.83 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
87.75 | 72.59 | 64.02 | 59.52 | |
Average Assets |
3,277.72 | 3,376.42 | 2,309.55 | 2,456.40 | |
Average Common Equity |
1,999.20 | 2,235.80 | 1,789.03 | 1,948.25 |
Columns are period end dates · fundamentals updated 4 Nov 2026